Search

Your search keyword '"Asghari S"' showing total 372 results
Start Over Author "Asghari S" Publication Year Range Last 10 years
372 results on '"Asghari S"'

1. A Fibroblast Growth Factor Antagonist Peptide Inhibits Breast Cancer in BALB/c Mice

Author

Jafarzadeh Mehrzad, Mousavizadeh Kazem, Joghataei Mohammad Taghi, Bahremani Mohammad Hashemi, Safa Majid, and Asghari S. Mohsen

Subjects
bfgf, peptide, angiogenesis, breast cancer, tumor growth, Biology (General), QH301-705.5
Abstract

Given the role of basic fibroblastic growth factor (bFGF) in tumor growth, it has been considered as a potential target for tumor therapy. In this study, we investigate the effect of bFGF antagonistic peptide on the growth and angiogenesis of 4T1 mammary carcinoma tumor (MCT) in BALB/c mice.

Published
2018
Full Text
View/download PDF

21. Synthesis, Radiolabeling, and Biodistribution Study of a Novel DOTA-Peptide for Targeting Vascular Endothelial Growth Factor Receptors in the Molecular Imaging of Breast Cancer.

Author

Ebrahimi, Fatemeh, Zargari, Nooshin Reisi, Akhlaghi, Mehdi, Asghari, S. Mohsen, Abdi, Khosrou, Balalaie, Saeed, Asadi, Mahboobeh, and Beiki, Davood

Subjects
VASCULAR endothelial growth factor receptors, VASCULAR endothelial growth factors, POSITRON emission tomography, RADIOCHEMICAL purification, PEPTIDES
Abstract

As angiogenesis plays a pivotal role in tumor progression and metastasis, leading to more cancer-related deaths, the angiogenic process can be considered as a target for diagnostic and therapeutic applications. The vascular endothelial growth factor receptor-1 (VEGR-1) and VEGFR-2 have high expression on breast cancer cells and contribute to angiogenesis and tumor development. Thus, early diagnosis through VEGFR-1/2 detection is an excellent strategy that can significantly increase a patient's chance of survival. In this study, the VEGFR1/2-targeting peptide VGB3 was conjugated with 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA), using 6-aminohexanoic acid (Ahx) as a spacer to prevent steric hindrance in binding. DOTA-Ahx-VGB3 was radiolabeled with Gallium-68 (68Ga) efficiently. An in vitro cell binding assay was assessed in the 4T1 cell line. The tumor-targeting potential of [68Ga]Ga-DOTA-Ahx-VGB3 was conducted for 4T1 tumor-bearing mice. Consequently, high radiochemical purity [68Ga]Ga-DOTA-Ahx-VGB3 (RCP = 98%) was prepared and stabilized in different buffer systems. Approximately 17% of the radiopeptide was internalized after 2 h incubation and receptor binding as characterized by the IC50 value being about 867 nM. The biodistribution and PET/CT studies revealed that [68Ga]Ga-DOTA-Ahx-VGB3 reached the tumor site and was excreted rapidly by the renal system. These features convey [68Ga]Ga-DOTA-Ahx-VGB3 as a suitable agent for the noninvasive visualization of VEGFR-1/2 expression. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

40. Additional file 1 of Conjugation of VEGFR1/R2-targeting peptide with gold nanoparticles to enhance antiangiogenic and antitumoral activity

Author

Zanjanchi, Pegah, Asghari, S. Mohsen, Mohabatkar, Hassan, Shourian, Mostafa, and Shafiee Ardestani, Mehdi

Subjects
cardiovascular system
Abstract

Additional file 1: Figure S1. (a) Peptide was purified as 90% by high-performance liquid chromatography (HPLC). (b) The molecular structure of the peptide and the disulfide bond formation was confirmed by electrospray ionization-mass spectrometry (ESI-MS). Figure S2. The verification of the size and the shape of synthesized GNP���VGB3 by FESEM. Figure S3. Ability of GNP, VGB3 and GNP���VGB3 in binding to VEGFR1, and VEGFR2 on HUVECs and their dose dependent manner. Figure S4. Ability of GNP, VGB3 and GNP���VGB3 in binding to p-VEGFR1, and p-VEGFR2 on HUVECs and their dose dependent manner.

Published
2022
Full Text
View/download PDF

46. Evaluating the impact of a champion on implementation of the Back Skills Training (BeST) programme in Canada: a mixed methods feasibility study protocol

Author

Hall, A, Richmond, H, Bursey, K, Hansen, Z, Williamson, E, Copsey, B, Albury, C, Asghari, S, Curran, V, Pike, A, Etchegary, H, and Lamb, S

Subjects
Canada, organisational development, Newfoundland and Labrador, change management, back pain, education & training (see medical education & training), Physical Therapists, primary care, Evidence Based Practice, pain management, Feasibility Studies, Humans, Low Back Pain, Randomized Controlled Trials as Topic
Abstract

Introduction There is global recognition that low back pain (LBP) should be managed with a biopsychosocial approach. Previous implementation of this approach resulted in low uptake and highlighted the need for ongoing support. This study aims to explore the feasibility of (i) training and using a champion to support implementation, (ii) using a cluster randomised controlled trial (RCT), (iii) collecting patient reported outcome measures in a Canadian public healthcare setting and to identify contextual barriers to implementation. Methods A pragmatic cluster RCT with embedded qualitative study with physiotherapists treating LBP in publicly funded physiotherapy departments in Newfoundland and Labrador, Canada. Participants will complete a previously developed online training course to equip them to deliver a biopsychosocial intervention for LBP. Clusters randomised to the intervention arm will receive additional support from a champion. A minimum champion training package has been developed based on known barriers in the literature. This includes strategies to target barriers relating to group-based scheduling issues, lack of managerial support, perceived patient factors such as addressing patient expectations for other types of treatments or selecting which patients might be best suited for this intervention, and anxiety about delivering something new. This package will be further codeveloped with study champions based on identified implementation barriers using the Behaviour Change Wheel. Clusters will be monitored for 6 months to assess champion and physiotherapist recruitment and retention, acceptability and implementation of the champion training, and the viability of conducting a cluster RCT in this setting. A purposive sample of physiotherapists will be interviewed from both arms. Ethics and dissemination This study was approved by Newfoundland and Labrador Health Research Ethics Authority in December 2018. Results will be disseminated to academic audiences through conferences and peer reviewed publications; to all study participants, their clinical leads, and patients with LBP. Trial registration number ClinicalTrials.gov Identifier: NCT04377529; Memorial University of Newfoundland Protocol Record 20190025; Pre-results.

Published
2020
Full Text
View/download PDF

50. A Controlled-Source Radio-Magnetotelluric Experiment in Aleksandrovka, Russia

Author

Fadavi Asghari, S., Smirnova, M., Shlykov, A., Tezkan, B., Saraev, A., and Yogeshwar, P.

Abstract

Radio-Magnetotelluric (RMT) method is based on measurements of the electromagnetic (EM) field of remote radio transmitters in a frequency range of 10 – 1000 kHz where CSRMT measures the EM field from a controlled-source in a wider frequency range of 1 – 1000 kHz. This, results to a higher signal to noise ratio compare to RMT method. Two perpendicular transmitters with 800 meters long, are used in this experiment. Therefore, the full impedance tensor and the tipper elements will be observed. In order to increase the data coverage, RMT measurements also carried out when the transmitter was off . These, also used to test the near-field condition. In this study, near-field is also been considered as well as far-field.

Published
2020

Catalog

Books, media, physical & digital resources
See catalog results